News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Albany Molecular Research, Inc. (AMRI) Announces Funded Research Collaboration with Navigen Pharmaceuticals, Inc.
April 13, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ:AMRI) announced today that it has initiated a research collaboration with Navigen Pharmaceuticals, Inc. focused on the development of new drug therapies.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Layoff Tracker
BioAtla Cuts Some 70% of Workforce as Company Considers Options
March 3, 2026
·
60 min read
·
BioSpace Editorial Staff
MASH
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
March 3, 2026
·
2 min read
·
Tristan Manalac
Layoffs
BioAtla Axes 70% of Staff, Explores Strategic Options
March 2, 2026
·
1 min read
·
Angela Gabriel
IPO tracker
Generate Clocks Largest IPO Since 2024 With $400M Raise
February 27, 2026
·
5 min read
·
Tristan Manalac